We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509
News

Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509

Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509
News

Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Sangamo BioSciences, Inc. announced the presentation of preliminary data from the Phase 2 clinical trial of its ZFP Therapeutic™ program to develop SB-509 as a treatment for amyotrophic lateral sclerosis (ALS) at a Work in Progress session at the 20th International Symposium on ALS/MND held in Berlin, Germany.

The preliminary data were from the first subjects enrolled in Sangamo's Phase 2 clinical trial, SB-509-801, and demonstrate an approximate doubling of frequency of improved muscle function in subjects with ALS who received two treatments of SB-509 (32%) compared to matched historic controls (17%). In early stage ALS clinical trials, an historic control is frequently used rather than a placebo to maximize the number of subjects receiving the drug.

Muscle function was assessed by muscle manual testing (MMT), a commonly used ALS endpoint which uses a manual method of functional assessment of 34 muscles over the whole body. In addition, a subset of subjects that showed an increase in muscle function over this period also demonstrated improvement in one or more additional end-points. These end-points include the Revised ALS Functional Rating Scale (ALSFRS-R) which is a validated rating instrument for monitoring the quality of life and progression of disability in patients with ALS and whose scores correlate significantly with survival, and forced vital capacity (FVC), a measure of lung function.

"We desperately need new therapeutics that will alter the relentless deterioration of muscle function that is characteristic of ALS," commented Jeffrey Rothstein, M.D., Ph.D., Director of the Robert Packard Center for ALS Research, Co-Director of the MDA/ALS Clinic and professor of Neurology at the Johns Hopkins University School of Medicine. "The ability to maintain muscle strength or delay its deterioration could have a significant impact on quality of life for persons with ALS."

SB-509 is a transcriptional activator of vascular endothelial growth factor (VEGF-A) which has been demonstrated to have a significant role in ALS. Mutations that reduce levels of VEGF-A expression are linked with progression to ALS and VEGF-A levels are reduced in the spinal fluid of patients with ALS.

In addition, in an apparent compensatory response, VEGF receptor levels are increased in both the blood vessels and the spinal cord in ALS patients.

"Preclinical data as well as clinical observations from our studies of SB-509 in diabetic neuropathy demonstrated that this ZFP Therapeutic has an effect on muscle function and we are very pleased to see evidence of a similar effect in subjects with ALS," stated Dale Ando, M.D., Sangamo's Vice President of Therapeutic Development and Chief Medical Officer.
Advertisement